Salvatore Chillemi, MD
Nephrology · Marietta, GANPI 1285839431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $220,630 of the $287,155 with a category attached, or 76.8%. 31 manufacturers reported payments, led by AstraZeneca at 33.8% of the total. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 964 payments — averaging $297.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$97K
- Mallinckrodt Hospital Products Inc.$55K
- Mallinckrodt Enterprises LLC$45K
- Amgen$28K
- Akebia Therapeutics Inc$17K
- Vifor Pharma, Inc.$15K
- plus $29K from 25 others
What the payments were for
- Consulting fees$16,3756%
- Speaking & faculty fees$220,63077%
- Travel & lodging$31,06411%
- Food & beverage$18,8427%
- Education$2030%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 211 | $97,179 |
| Mallinckrodt Hospital Products Inc. | 97 | $55,230 |
| Mallinckrodt Enterprises LLC | 61 | $45,403 |
| Amgen(2 entities) | 162 | $28,361 |
| Akebia Therapeutics Inc | 51 | $17,120 |
| Vifor Pharma, Inc. | 64 | $14,615 |
| Ardelyx, Inc. | 26 | $13,873 |
| Bayer | 26 | $4,266 |
| Calliditas Therapeutics US Inc. | 30 | $3,675 |
| Aurinia Pharma U.S., Inc. | 8 | $2,993 |
| Travere Therapeutics, Inc. | 33 | $915 |
| Otsuka America Pharmaceutical, Inc. | 44 | $905 |
| Alnylam Pharmaceuticals Inc. | 16 | $417 |
| OPKO Pharmaceuticals, LLC | 39 | $350 |
| Fresenius USA Marketing, Inc. | 22 | $303 |
| ANI Pharmaceuticals, Inc. | 15 | $289 |
| Novartis | 11 | $272 |
| GSK | 11 | $208 |
| Sanofi | 7 | $151 |
| Baxter Healthcare | 2 | $104 |
| Daiichi Sankyo Inc. | 5 | $102 |
| Novo Nordisk | 4 | $86 |
| Ultragenyx Pharmaceutical Inc. | 4 | $65 |
| Boehringer Ingelheim | 3 | $56 |
| Lilly USA, LLC | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Shield Therapeutics Inc | 2 | $42 |
| Apellis Pharmaceuticals, Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $17 |
| Vantive US Healthcare LLC | 1 | $16 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$287,155 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 53 | $70,208 |
| XphozahTenapanor Hcl | 20 | $61,495 |
| VelphoroSucroferric Oxyhydroxide | 11 | $43,159 |
| AuryxiaFerric Citrate | 12 | $36,241 |
| ProsolParenteral Amino Acid 20% No.1 | 64 | $33,147 |
| FarxigaDapagliflozin Propanediol | 34 | $28,518 |
| Lanthanum Carbonate | 22 | $21,573 |
| JardianceEmpagliflozin | 13 | $20,469 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 52 | $15,566 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $14,302 |
| Sevelamer Carbonate | 27 | $8,340 |
| ClinisolParenteral Amino Acid 15% No.5 | 28 | $5,041 |
| Tolvaptan | 12 | $4,368 |
| Nifedipine ErNifedipine | 64 | $2,936 |
| Midodrine Hcl | 19 | $1,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $4,266 | $70,20853 claims |
| Fresenius USA Marketing, Inc.Velphoro | $303 | $43,15911 claims |
| Akebia Therapeutics IncAuryxia | $17,120 | $36,24112 claims |
| AstraZenecaFarxiga | $97,179 | $28,51834 claims |
| Boehringer IngelheimJardiance | $56 | $20,46913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Marietta
- Indira ChervuMarietta$12K
- Muhammad JabriMarietta$6K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
- Rajendran AlappanColumbus$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.